Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)

Eisai

Programmatic AI Search & Model Visibility Audit

Share of Model (SOM)
20.0%
+1.0% 30-Day Momentum
🧠 Neural Valency:Neutral

Algorithmic Threat Detection

Primary Competitor Threat
Biogen
Competitor Displacement Rate
8.0%

Competitors are displacing Eisai in 8.0% of high-intent buyer queries.

Algorithmic Rationale: Algorithmic focus on breakthrough treatments by competitors like Biogen is capturing significant SERP real estate. Eisai needs to highlight its pipeline and clinical trial successes more prominently.
Missing AI Citations:
[clinicaltrials.gov][pubmed.ncbi.nlm.nih.gov]
⚠️ Identified Vulnerability:Pipeline Visibility
Primary Threat Identified:Biogen
Target Persona:Neurology Researchers
🚨 Threat Velocity:5/10
Unlock Full Threat Report (30 Free Credits)